Business profile & competitive position
ResMed Inc. operates in the Healthcare sector, specifically the Medical – Instruments & Supplies industry. The company is a global developer and marketer of cloud-connected medical devices and software focused on sleep and breathing health. Its hardware lineup includes CPAP, APAP, bilevel, and ventilation devices, plus masks, diagnostics, dental devices, and accessories. Beyond devices, ResMed provides cloud-based Residential Care Software to home medical equipment providers, home health agencies, hospices, skilled nursing facilities, and senior living operators. Products and services are sold in more than 140 countries through subsidiaries and independent distributors.
ResMed reports through two segments: Sleep and Breathing Health, and Residential Care Software. In fiscal 2026, devices generated roughly 51% of net revenue, masks/diagnostics/accessories contributed about 37%, and software accounted for around 12%. As of its most recent 10-K, the company had more than 35 million cloud-connected devices on its AirView platform and over 12 million patients registered on its myAir patient engagement app, while employing approximately 11,370 people.
The reported profitability figures support the idea of a durable, high-quality business. ResMed’s net margin is 26.9% and its return on equity is 23.9%, both well above what is typical for many capital-intensive manufacturers. Those numbers, combined with the installed base of connected devices and recurring revenue from masks, accessories, and software, point to a business with significant pricing discipline and customer retention in its core sleep-apnea market.
Financial posture
ResMed’s current market capitalization is $34.9 billion, with a trailing P/E ratio of 23.1. The stock trades at $240.8 with an RSI of 69.2, just below the common 70 overbought threshold, and it sits notably above its 50-day exponential moving average of $217.76. Beta is 0.75, suggesting the stock has historically moved less dramatically than the overall market.
The valuation sits at a moderate premium to the broader healthcare complex, but the premium is backed by a 26.9% net margin and 23.9% ROE. Recent earnings momentum has been positive on an absolute basis: reported EPS advanced from $2.55 in October 2025, to $2.81 in January 2026, $2.86 in April 2026, and $2.95 in August 2026. The next scheduled report is October 29, 2026 after the close, with a consensus EPS estimate of $2.69, a sequential step-down from the August result that likely reflects seasonality and mix considerations heading into fiscal 2027.
Strategic priorities & outlook
ResMed’s most recent 10-K outlines a strategy built around deepening its core sleep and breathing franchise while expanding its connected-care ecosystem. Management’s near-term operational focus includes:
- Growing and differentiating the core sleep-apnea portfolio by integrating AI and machine learning, simplifying care pathways, and expanding home diagnostics, including NightOwl and the VirtuOx IDTF acquisition.
- Accelerating market growth through awareness and education aimed at patients, physicians, and special-interest groups for sleep apnea, COPD, and related comorbidities.
- Capitalizing on adjacent sleep and breathing-health opportunities such as COPD, neuromuscular disease, and restless legs syndrome, the latter via the Noctrix acquisition.
- Investing in an integrated, intelligent digital-health ecosystem delivered at home, anchored by AirView remote monitoring and the myAir patient engagement platform.
A notable portfolio move is the June 2026 agreement to sell the MatrixCare business for $490 million in cash. ResMed expects the transaction to close in the first quarter of fiscal 2027 and says the divestiture is designed to sharpen focus on core sleep, breathing, and connected home-based healthcare. The cloud-installed base—more than 35 million devices on AirView and over 12 million myAir registrations—remains central to the recurring-data and software strategy.
Macro & geopolitical exposure
As a Medical – Instruments & Supplies company, ResMed faces exposures that are common across the healthcare-device space rather than unique to the firm. Reimbursement policy is a persistent factor: Medicare, Medicaid, and private-payer decisions on sleep-apnea therapy and home respiratory equipment can affect volume and pricing in core markets. The industry is highly regulated, with FDA and international-equivalent approvals, quality-system requirements, and post-market surveillance governing how devices come to market.
Tariffs and supply-chain disruptions can affect the cost of components and finished goods, especially given ResMed’s global footprint across more than 140 countries. Currency translation is another consideration: a meaningful portion of sales is generated outside the United States, so exchange-rate swings can influence reported revenue and margin. Product-liability litigation and shareholder class-action investigations are recurring features of the medical-device landscape, and the August 2025 law-firm probe fits that pattern. Finally, long-term demand is supported by demographic trends such as aging populations and rising diagnosis rates for sleep apnea, COPD, and related chronic conditions.
Recent developments
ResMed has appeared in several news items over the final days of August 2026, sending mixed sentiment signals:
- August 30, 2026 — defenseworld.net reported that the Canada Pension Plan Investment Board opened a new position in ResMed.
- August 27, 2026 — prnewswire.com announced that Pomerantz Law Firm is investigating claims on behalf of investors of ResMed.
- August 27, 2026 — globenewswire.com reported ResMed’s participation in the 24th Annual Morgan Stanley Global Healthcare Conference.
- August 27, 2026 — defenseworld.net reported that American Capital Management Inc. purchased 228,458 shares of ResMed.
The institutional accumulation headlines suggest larger investors are adding exposure around current levels, while the law-firm investigation is a routine reminder that medical-device companies regularly face shareholder litigation. The Morgan Stanley conference appearance is a standard investor-relations event and may offer management a venue to discuss the MatrixCare divestiture and fiscal 2027 priorities.
Earnings behavior & post-earnings drift
ResMed has a strong recent earnings record. Over the last eight reported quarters, the company beat estimates six times, for a beat rate of 86%, with an average earnings surprise of 2.6%. Despite the consistency, the average 5-day price move after earnings across those quarters is just 0.24%, classified as flat drift. That divergence is important: beating EPS alone does not guarantee a positive short-term price reaction.
The August 6, 2026 quarter illustrates this dynamic clearly. ResMed reported EPS of $2.95 against an estimate of $2.89, a 2.1% surprise and a beat, yet the stock fell 5.06% the next day before recovering to a 1.57% gain over the following five trading days. The April 30, 2026 report was similar: a $2.86 actual versus a $2.80 estimate (2.1% surprise) was followed by a -4.11% next-day move and a -3.24% five-day drift.
The January 29, 2026 report was the standout exception among the last four: a $2.81 actual versus $2.74 estimate (2.6% surprise) produced a +0.27% next-day move and a +3.66% five-day drift. The October 30, 2025 quarter, a $2.55 actual versus $2.51 estimate (1.6% surprise), saw a -2.13% next-day drop and a -1.03% five-day drift.
The takeaway from this history is that the market’s real expectation around ResMed’s quarterly reports appears to extend beyond the bottom-line EPS number. Guidance, margin commentary, device mix, and commentary on the MatrixCare sale or home-diagnostics rollout may carry as much weight as whether the company clears the $2.69 consensus estimate when it reports on October 29, 2026 after the close.
Frequently Asked Questions
What does ResMed primarily sell?
ResMed sells cloud-connected medical devices and software for sleep and breathing health, including CPAP, APAP, bilevel, and ventilation devices, masks, diagnostics, dental devices, and connected-care software. It also provides Residential Care Software to home medical equipment, home health, hospice, skilled nursing, and senior living providers.
How has RMD historically behaved after earnings beats?
ResMed has beaten estimates in 6 of the last 8 quarters (86%), with an average surprise of 2.6%. However, the average 5-day post-earnings move is only 0.24%, classified as flat. For example, the August 6, 2026 beat produced a -5.06% next-day drop before a 1.57% five-day recovery.
What strategic shift is ResMed making heading into fiscal 2027?
In June 2026, ResMed agreed to sell its MatrixCare business for $490 million in cash, with closing expected in the first quarter of fiscal 2027. Management says the move is intended to sharpen focus on core sleep, breathing, and connected home-based healthcare.
For a deeper dive into how institutional analysts are weighing ResMed’s valuation, earnings setup, and strategic direction ahead of the October 29, 2026 report, readers should review the full institutional verdict on the ticker page rather than relying on any single data point.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-08-06 | $2.95 | $2.89 | +2.1% | -5.06% | +1.57% |
| 2026-04-30 | $2.86 | $2.8 | +2.1% | -4.11% | -3.24% |
| 2026-01-29 | $2.81 | $2.74 | +2.6% | +0.27% | +3.66% |
| 2025-10-30 | $2.55 | $2.51 | +1.6% | -2.13% | -1.03% |
| 2025-07-31 | $2.55 | $2.55 | 0% | - | - |
| 2025-04-23 | $2.37 | $2.38 | -0.4% | - | - |
Previous RMD editions
Get the institutional verdict on RMD
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the RMD verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.